ARTICLE | Company News
Helsinn, Zealand Pharma deal
December 15, 2008 8:00 AM UTC
Zealand granted Helsinn an exclusive, worldwide license to develop and commercialize ZP1846 in all indications. The glucagon-like peptide-2 receptor ( GLP-2) agonist has completed Phase I testing to...